Drug Trial Radar · NCT03181828
Manipulating the Gut Microbiome Study
Last checked: Nov 20, 2026Latest source record: Dec 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Mar 24, 2017
Primary completion
Jun 5, 2018
Study completion Jun 5, 2018
Sponsor
- Lead sponsor
- Nicholas Ah MewAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective is to determine if acetohydroxamic acid (AHA) can prevent hydrolysis of urea by inhibiting the bacterial urease of gut flora of both healthy control adults as well as adults with urea cycle disorders
Conditions
- Urea Cycle Disorder
Interventions
Acetohydroxamic Acid Oral TabletDrug
A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
No treatmentOther
No treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Atom Percent Excess of 13CO2Time frame: Time +0 minutes, +30 minutes, +60 minutes, +90 minutes, +120 minutes, +180 minutes, and +240 minutes from time of infused [13C] Urea IV
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's National Medical Center
Washington D.C., District of Columbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.